Clinical Trials

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT04288089 2026-02-27

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

31 enrolled 12 charts

Breast Neoplasms

NCT04546009 2026-02-20

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

992 enrolled

Breast Neoplasms

NCT03332797 2026-02-13

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

181 enrolled

Breast Neoplasms

NCT05501886 2026-02-10

VIKTORIA-1

701 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05909397 2026-02-10

VERITAC-3

59 enrolled

Breast Neoplasms

NCT06757634 2026-02-05

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

674 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03616587 2026-01-28

SERENA-1

396 enrolled

Breast Neoplasms

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

196 enrolled

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Breast Neoplasms

NCT04671615 2025-12-10

A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

559 enrolled 26 charts

Breast Neoplasms

NCT04735367 2025-12-09

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

42 enrolled 7 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

35 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Breast Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT05266105 2025-11-24

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

60 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

779 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02297438 2025-10-27

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Phase 3 Completed

340 enrolled 29 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04567420 2025-10-16

DARE

Phase 2 Recruiting

70 enrolled

Breast Neoplasms

NCT04711252 2025-10-14

SERENA-4

1,370 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

NCT05216432 2025-09-22

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Phase 1 Recruiting

930 enrolled

Breast Neoplasms

NCT04478266 2025-09-11

AMEERA-5

Phase 3 Terminated

1,068 enrolled 21 charts

Breast Neoplasms

NCT07096024 2025-08-28

A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market

1,772 enrolled

Breast Neoplasms

NCT04224272 2025-08-01

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Phase 2 Completed

51 enrolled 10 charts

Breast Neoplasms

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

46 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT06307457 2025-06-29

A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

604 enrolled 20 charts

Breast Neoplasms

NCT05759949 2025-05-16

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Phase 1 Completed

41 enrolled

Breast Neoplasms

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

6 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT06757335 2025-01-03

A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer

204 enrolled

Breast Neoplasms

NCT04818632 2024-12-17

AZD9833

Phase 1 Completed

28 enrolled

Breast Neoplasms

NCT05293964 2024-11-29

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

214 enrolled

Breast Neoplasms

NCT01740427 2024-11-14

PALOMA-2

Phase 3 Completed

666 enrolled 22 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04060862 2024-11-08

IPATunity150

Phase 1 Terminated

20 enrolled 11 charts

Breast Neoplasms

NCT05012644 2024-10-08

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

197 enrolled 16 charts